Codetta Bio is a technology company.
Codetta Bio has raised $15.0M across 1 funding round.
Key people at Codetta Bio.
Codetta Bio has raised $15.0M in total across 1 funding round.
Codetta Bio has raised $15.0M in total across 1 funding round.
Codetta Bio's investors include Anzu Partners.
Key people at Codetta Bio.
Codetta Bio is a biotechnology company founded in 2021 that develops advanced multi-omics biomarker measurement tools, focusing on a fully integrated platform for simultaneous DNA, RNA, and protein analysis from a single sample.[1][2][3][5] Its Concerto System combines digital PCR, real-time PCR, and immunoPCR technologies on a single instrument, enabling high-sensitivity, high-throughput multiplexing in just a 3-hour run, primarily serving translational research, clinical trials, and diagnostic development.[1][2][5] The company has raised $17.26M in funding, reaching Series A-II stage, with its Mosaic Score rising +129 points recently, signaling strong market potential.[1]
Codetta Bio emerged in 2021 from the vision of co-founder Michael Ramsey, a National Academy of Engineering member with over 300 peer-reviewed papers, 165 issued patents, and expertise in microfluidics and chemical analysis.[3] Ramsey's background in pioneering optical and analytical technologies laid the groundwork for the company's innovative platform, driven by the need for optimal sensitivity and efficiency in biomarker detection from limited samples.[3] Early traction built on this foundation, with the company basing operations in Morrisville/Durham, North Carolina, and securing $17.26M in funding, including a $2.26M round 8 months ago, amid leadership additions like strategic experts in corporate strategy and genomics.[1][2]
Codetta Bio rides the multi-omics revolution in precision medicine, where integrating genomic, transcriptomic, and proteomic data from single samples accelerates biomarker discovery for clinical trials and personalized diagnostics.[1][3][5] Timing aligns with surging demand for scalable, cost-effective tools amid NGS limitations in plexing and throughput, fueled by market forces like rising clinical trial complexity and wellness-focused research on genetic/environmental factors.[1][4] By enabling easier multiplexing, it influences the ecosystem, potentially standardizing multi-omics in labs and fine-tuning patient selection, bridging research-to-clinic gaps.[1][3]
Codetta Bio is poised to commercialize its Concerto System, expanding into broader diagnostic adoption as multi-omics matures.[1][4][5] Trends like AI-driven analytics and single-sample efficiency will amplify its edge, with recent funding and leadership bolstering scale-up.[1] Its influence may evolve into an industry standard for biomarker tools, harmonizing data like a codetta in biotech's symphony, empowering precision health breakthroughs.[3][5]
Codetta Bio has raised $15.0M across 1 funding round. Most recently, it raised $15.0M Series A in April 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Apr 1, 2022 | $15.0M Series A | Anzu Partners |
